148 related articles for article (PubMed ID: 7302264)
1. OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro.
Smith JB; Jubiz W
Prostaglandins; 1981 Sep; 22(3):353-63. PubMed ID: 7302264
[TBL] [Abstract][Full Text] [Related]
2. Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581.
Uotila P; Matintalo M; Dahl ML
Prostaglandins Leukot Med; 1983 Nov; 12(3):299-303. PubMed ID: 6419237
[TBL] [Abstract][Full Text] [Related]
3. Effect of OKY-046, a selective thromboxane inhibitor, on prostaglandin production and function of pregnant rat uteri and platelets.
Ghodgaonkar RB; Dubin NH
Prostaglandins Leukot Med; 1987 Jan; 26(1):33-46. PubMed ID: 3468521
[TBL] [Abstract][Full Text] [Related]
4. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
5. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
6. Lithium stimulates thromboxane B2 formation in human platelets.
Imandt L; Tijhuis D; Wessels H; Haanen C; van den Berg R; Thomas C
Prostaglandins Med; 1981 Nov; 7(5):421-9. PubMed ID: 6798588
[TBL] [Abstract][Full Text] [Related]
7. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats.
Gomi T; Ikeda T; Ishimitsu T; Uehara Y
Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692
[TBL] [Abstract][Full Text] [Related]
8. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise.
Shikano M; Ito T; Ogawa K; Satake T
Jpn Heart J; 1987 Sep; 28(5):663-74. PubMed ID: 3323562
[TBL] [Abstract][Full Text] [Related]
9. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M
Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of platelet aggregation and thromboxane production by pinacidil.
Goodman RP; Little DM; Wright JT
Prostaglandins Leukot Med; 1985 Aug; 19(2):115-22. PubMed ID: 3931098
[TBL] [Abstract][Full Text] [Related]
11. A new approach to antithrombotic therapy--evaluation of combined therapy of thromboxane synthetase inhibitor and very low dose of aspirin.
Nagatsuka K; Uyama O; Nakabayashi S; Yoneda S; Kimura K; Kamada T
Stroke; 1985; 16(5):806-9. PubMed ID: 3931302
[TBL] [Abstract][Full Text] [Related]
12. Effect of cetiedil on platelet aggregation and thromboxane synthesis.
Yamaguchi A; Asakura T; Tanoue K; Yamazaki H
Thromb Res; 1985 Feb; 37(3):391-400. PubMed ID: 2986312
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of collagen induced thromboxane release from platelets of different species: implications for human atherosclerosis models.
Leach CM; Thorburn GD
Prostaglandins; 1982 Jul; 24(1):47-59. PubMed ID: 7122912
[TBL] [Abstract][Full Text] [Related]
14. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord].
Morimoto K; Ikata T; Tounai T
Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous infusion of OKY-1581 (sodium-(E)-3-[4-(3-pyridylmethyl)phenyl] -2-methylacrylate) on circulatory thromboxane A2 and prostacyclin levels in anaesthetized baboon.
Roy AC; Adaikan PG; Karim SM
Prostaglandins Med; 1981 Sep; 7(3):253-9. PubMed ID: 7029585
[No Abstract] [Full Text] [Related]
16. Nicergoline, an anti-aggregating agent which inhibits release of arachidonic acid from human platelet phospholipids.
Lagarde M; Guichardant M; Ghazi I; Dechavanne M
Prostaglandins; 1980 Apr; 19(4):551-7. PubMed ID: 7384555
[TBL] [Abstract][Full Text] [Related]
17. Rabbit nephrotoxic nephritis: effect of a thromboxane synthetase inhibitor on evolution and prostaglandin excretion.
Shinkai Y; Cameron JS
Nephron; 1987; 47(3):211-9. PubMed ID: 3317092
[TBL] [Abstract][Full Text] [Related]
18. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531
[No Abstract] [Full Text] [Related]
19. Effects of ethanol intoxication and hangover on plasma levels of thromboxane B2 and 6-keto-prostaglandin F1 alpha and on thromboxane B2 formation by platelets in man.
Kangasaho M; Hillbom M; Kaste M; Vapaatalo H
Thromb Haemost; 1982 Oct; 48(2):232-4. PubMed ID: 7179202
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets.
Uotila P; Matintalo M
Prostaglandins Leukot Med; 1984 Apr; 14(1):41-6. PubMed ID: 6427791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
